Recording: PARP inhibitors in prostate cancer management
Recording in collaboration with the EAU Section of Oncological Urology Organised by the European School of Urology and the EAU Section of Oncological Urology. This recording will focus on the role of poly-ADP ribose polymerase (PARP) inhibitors in prostate cancer (PCa) management.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | Not approved |
| Duration | Approx. 60 minutes |
ARP inhibitors have emerged as a game-changer in PCa treatment, offering new therapeutic options for patients with advanced disease. How do they fit into current clinical practice? What are the latest developments, patient selection criteria, and practical considerations for their use?
Join our discussion as we explore the role of PARP inhibitors, review key clinical data, and discuss their integration into PCa management.
Speakers:
- Assoc. Prof. J. Gómez Rivas (ES)
- Assoc. Prof. J. Aning (GB)
- Drs. C. Mercinelli (IT)
- Prof. Dr. A.S. Merseburger (DE)
This recording is brought to you in collaboration with the EAU Section of Oncological Urology.
Acknowledgment
This activity is supported by an educational grant from our industry partner, with no involvement in the programme or speaker selection.